In Vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 2194-2197

  Tyrrell, Kerin L ^a   Citron, Diane M ^a   Warren, Yumi A ^a   Goldstein, Ellie J C ^a  

^a R M ALDEN RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CLINDAMYCIN; DAPTOMYCIN; IMIPENEM; LINEZOLID; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TD 1792; UNCLASSIFIED DRUG; VANCOMYCIN;

ACTINOMYCES; AGAR DILUTION; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; CLOSTRIDIUM; CLOSTRIDIUM CLOSTRIDIOFORME; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INNOCUUM; CLOSTRIDIUM PERFRINGENS; CLOSTRIDIUM RAMOSUM; CORYNEBACTERIUM; EUBACTERIUM; FUSOBACTERIUM; IN VITRO STUDY; LACTOBACILLUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PORPHYROMONAS; PREVOTELLA; PRIORITY JOURNAL; PROPIONIBACTERIUM; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; CEPHALOSPORINS; COLONY COUNT, MICROBIAL; CORYNEBACTERIUM; CULTURE MEDIA; DAPTOMYCIN; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN;

EID: 84858648112     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06274-11     Document Type: Article

References (22)

1. Bessman AN, Geiger PJ, Canawati H. 1992. Prevalence of Corynebacteria in diabetic foot infections. Diabetes Care 15:1531-1533.
2. Blais J, et al. 2007. Bactericidal acivity, postantibiotic effect, and frequency of resistance studies with TD-1792, abstr C11475. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
3. Blais J, Lewis SR, Krause KM, Benton BM. 2012. Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic. Antimicrob. Agents Chemother. 56:1584-1587.
4. Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA. 2007. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J. Clin. Microbiol. 45:2819-2828. (Pubitemid 47417321)
5. Clinical and Laboratory Standards Institute. 2006. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guidelines. CLSI document M45-A. CLSI, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 7th ed. CLSI document M11-A7. CLSI, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. CLSI, Wayne, PA.
8. Decousser JW, Bourgeois-Nicolaos N, Doucet-Populaire F. 2007. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrugresistant Gram-positive bacteria. Expert Rev. Anti Infect. Ther. 5:557-571. (Pubitemid 47250131)
9. Difuntorum S, et al. 2007. In vitro and in vivo evidence for a multivalent mode of action of TD-1792 against Staphylococcus aureus, abstr F1-2110. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. Fritsche TR, Blais J, Jones RN. 2007. In vitro evaluation of TD-1792, a novel antimicrobic with potent gram-positive activity, abstr E-1627. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
11. Goldstein EJ, et al. 2004. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob. Agents Chemother. 48:2149-2152. (Pubitemid 38691612)
12. Goldstein EJ, et al. 2006. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections. Antimicrob. Agents Chemother. 50:2875-2879. (Pubitemid 44198720)
13. Jousimies-Somer HR, et al. 2002. Wadsworth-KTL anaerobic bacteriology manual. Star Publishing, Belmont, CA.
14. Krause KM, Difuntorum S, Blais J, Turner SD, Marquess D. 2007. TD-1792, a new antibiotic with improved in vitro activity, abstr E-1626. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
15. Lentino JR, Narita M, Yu VL. 2008. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur. J. Clin. Microbiol. Infect. Dis. 27:3-15. (Pubitemid 350197870)
16. Leuthner KD, Vidaillac C, Cheung CM, Rybak MJ. 2010. In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates. Antimicrob. Agents Chemother. 54:3799-3803.
17. Lipsky BA, et al. 2005. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 366:1695-1703. (Pubitemid 41587448)
18. Long DD, et al. 2008. Exploring the positional attachment of glycopeptide/ beta-lactam heterodimers. J. Antibiot. (Tokyo) 61:603-614.
19. Murray PR, et al. 2007. Manual of clinical microbiology. ASM Press, Washington, DC.
20. Pathare NA, Bal A, Talvalkar GV, Antani DU. 1998. Diabetic foot infections: a study of microorganisms associated with the different Wagner grades. Indian J. Pathol. Microbiol. 41:437-441.
21. Sotto A, Bouziges N, Jourdan N, Richard JL, avigne JP. 2007. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers. Pathol. Biol. (Paris) 55:398-406. (Pubitemid 350017721)
22. Traczewski MM, Brown SD. 2007. TD-1792: in vitro bactericidal activity against staphylococci, abstr E-1625. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.